Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05109364 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Terazosin and Parkinson's Disease Extension Study

StatusActive, Not Recruiting
PhasePhase 2
Started2022-09-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 2, 2026 (before its estimated March 10, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-26
Recruiting→Active, Not Recruiting Study Identification, Study Status, Contacts/Locations, References v6
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-11-01→2026-03-10
Completion date2025-11-01→2026-03-10
Study sitesdetails revised at 1 of 1 site
Publicationsdetails revised at 78 of 78 entries
2024-11-22
Study Identification, Study Status, Contacts/Locations, References v5
Study sitescontacts updated at 1 of 1 site
Publicationsdetails revised at 78 of 78 entries
2023-10-04
Study Status, Outcome Measures, Eligibility, Contacts/Locations v4
Secondary endpointsdetails revised at 2 of 4 entries
2022-08-23
Study Status, Sponsor/Collaborators v3
Re-verified, no change to tracked fields
2022-08-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2021-11-23→2022-09-23
Study sites0→1
2021-11-22
Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v1
Start date2021-11-01→2021-11-23
Eligibility criteria+215 characters
[...] ive Concurrent dementia defined by a score lower than 22 on theThe Montreal Cognitive Assessment (MoCA) Concurrent severe depression defined by a Beck Depression Inventory-Fast Screen (BDI fast screen) score greater than 13 Comorbidities related to sympathetic nervous system (SNS) hyperactivity Heart failure (LVEF <45%) Recent myocardial revascularization (<12 weeks) Hypertension (systolic blood pressure SBP>150mmHg (millimeters of mercury) or diastolic blood pressure DBP>100mmHg) Chronic Atrial fibrillation Concurrent Use of Beta-adrenergic antagonist Diabetes mellitus Chronic Obstructive Pul [...] [...]
Secondary endpoints4 entries, revised
Heart Rate Variability Analysis (HRV) compared to MIBG results in predicting RBD convertionconversion to PD/other synucleinopathies
Primary endpoints1 to 3 entries
Changes in 123I-MIBG - Washout ratio (WR) Changes in 123I-MIBG reuptake - early Heart to Mediastinal ratio (H/M) Changes in 123I-MIBG reuptake - late Heart to Mediastinal ratio (H/M)
Study description+109 characters
[...] ive post-synaptic a1-adrenergic blocker terazosin on serial 123 Ioflupane Dopamine Transporter single-photon emission-computed tomography (123I-FP-CIT DAT-SPECT) in a population of subjects with defined pre-motor PD risks [...] tion, depression and color vision abnormality) and abnormal Iodine-123 meta-iodobenzylguanidine (123I-MIBG) uptake. Imaging changes will be correlated to the presence [...] cardiac autonomic function tests. The rate of RBD clinical phenoconversionconversion to PD will be estimated and compared to available data in the literature.
2021-10-26
Original filing
The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.
Trial Details
NCT Number NCT05109364
Lead Sponsor Cedars-Sinai Medical Center
Conditions Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Enrollment 15 participants
Start Date 2022-09-23
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-02